Colon-Targeted Micronutrient Formulation for SCFA and Butyrate Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations fail to effectively increase short-chain fatty acids (SCFAs) and butyrate synthesis, modulate microbiome diversity, and improve gut barrier function and immune responses, leading to conditions like inflammatory bowel diseases and metabolic disorders.
Innovation Solution
A delayed release formulation containing micronutrients such as riboflavin, vitamins, and omega-3 fatty acids is administered to enhance SCFA production, increase microbiome diversity, promote butyrate synthesis, and improve gut barrier function by targeting the large intestine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional formulations are used, then the formulations are simple and easy to manufacture, but they fail to effectively increase SCFAs and butyrate synthesis, modulate microbiome diversity, and improve gut barrier function
Solution Approach 1:
The patent employs composite material principles by combining multiple micronutrients (riboflavin, vitamins A, C, D, E, K, B1, B6, B12, folic acid, biotin, omega-3 fatty acids) with specific bacteria strains (Bifidobacterium, Akkermansia, Faecalibacterium) and prebiotic fibers in a single formulation. This composite approach synergistically enhances SCFA and butyrate synthesis, modulates microbiome diversity, and improves gut barrier function, resolving the contradiction between formulation simplicity and functional effectiveness.
Solution Approach 2:
The patent merges multiple functional components including micronutrients, probiotic bacteria, and prebiotic fibers into a unified formulation system. This combination allows the simultaneous achievement of increasing SCFA levels, enhancing butyrate synthesis, modulating microbiome diversity, and improving gut barrier function, thereby transforming a simple formulation into a multi-functional therapeutic composition.
2Reliability
If conventional formulations are used, then the formulations are easy to manufacture, but they fail to modulate microbiome diversity and abundance of beneficial bacteria
Solution Approach 1:
The formulation integrates multiple micronutrients with specific probiotic bacteria strains and prebiotic fibers to create a composite system that effectively modulates microbiome diversity and abundance. This composite structure enables the simultaneous enhancement of beneficial bacteria (Bifidobacterium, Akkermansia, Faecalibacterium) while maintaining manufacturability through standardized formulation processes.
3Reliability
If conventional formulations are used, then the formulations are simple, but they fail to improve gut barrier function and stimulate immune responses
Solution Approach 1:
The patent employs a composite formulation combining micronutrients, probiotics, and prebiotics that synergistically improves gut barrier function and stimulates immune responses. The multifactorial composition addresses the complexity-barrier function contradiction by providing comprehensive support for intestinal health through multiple active components working together.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation increases SCFA concentration, microbiome diversity, microbial abundance, and gut barrier function, reducing gas production and stimulating immune responses, thereby treating or preventing disorders associated with low SCFA levels and impaired gut integrity.
Implementation Method 1
The major products from the microbial fermentative activity in the gut are SCFAs—in particular, acetate, propionate, and butyrate
Implementation Method 2
A delayed release formulation containing micronutrients such as riboflavin, vitamins, and omega-3 fatty acids is administered to enhance SCFA production
Data Source
AI summary
Various benefits to intestinal health are made by delivery of an active agent to the colon of an animal, including a human. Active ingredients include of riboflavin, vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, β-carotene, vitamin B1, niacin, vitamin B5, vitamin B6, biotin, vitamin B12, omega-3 fatty acids and combinations thereof. Benefits include increased concentration of at least one short-chain fatty acid its salt thereof in the intestine, increased microbiome diversity in the intestine, increased beneficial bacteria in the intestine, increased the butyrate synthesis pathway in the intestine, improved barrier function of the intestine, reduced redox potential of the gut, reduced amount of gas produced in the intestine; and stimulation of intestinal immune responses.